Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch

WARREN, N.J., July 16, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that following the completion and deployment of the alpha version of PredicTcell™, a proprietary AI-driven target discovery platform, the Company now plans to expand Tevogen.AI to include patient data against identified targets.

Read more at globenewswire.com